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a b s t r a c t
Consistent with evidence of a strong correlation between interferon gamma (IFNγ) production and
rabies virus (RABV) clearance from the CNS, we recently demonstrated that engineering a pathogenic
RABV to express IFNγ highly attenuates the virus. Reasoning that IFNγ expression by RABV vaccines
would enhance their safety and efﬁcacy, we reverse-engineered two proven vaccine vectors, GAS and
GASGAS, to express murine IFNγ. Mortality and morbidity were monitored during suckling mice
infection, immunize/challenge experiments and mixed intracranial infections. We demonstrate that
GASγ and GASγGAS are signiﬁcantly attenuated in suckling mice compared to the GASGAS vaccine. GASγ
better protects mice from lethal DRV4 RABV infection in both pre- and post-exposure experiments
compared to GASGAS. Finally, GASγGAS reduces post-infection neurological sequelae, compared to
control, during mixed intracranial infection with DRV4. These data show IFNγ expression by a vaccine
vector can enhance its safety while increasing its efﬁcacy as pre- and post-exposure treatment.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Rabies is an important zoonotic disease that is estimated to kill
at least 60 000 people worldwide each year (Martinez, 2000). It is
caused by the rabies virus, a non-segmented, negative-strand
lyssavirus in the Rhabdoviridae family. The majority of rabies
deaths occurs from rabid dog bites in developing countries where
medical resources are limited and/or a lack of awareness about the
risk of RABV exposure exists (Knobel et al., 2005).
PEP readily prevents development of clinical rabies and death
when given soon after exposure to a rabid animal (Franka et al.,
2009). Unfortunately, because many do not have access to proper
medical care, whether for ﬁnancial or logistical reasons, or may
not recognize a potential RABV exposure, prompt administration
of rabies PEP to at-risk individuals is not always achieved (Joseph
et al., 2013). In these cases RABV enters the brain, clinical rabies
develops and the infected individuals almost invariably die. There-
fore, there is a great need to decrease RABV infection in dogs (and
other reservoirs) and to develop new therapeutics to successfully
extend the window of successful post-exposure treatment from
days to perhaps weeks or months. Live-attenuated vaccines are
promising candidates to fulﬁll both these needs. They can be
produced economically and induce long-lasting immunity with a
single dose. Furthermore, superinfection with attenuated RABV
has successfully protected animals exposed to lethal RABV.
Early superinfection experiments in dogs showed protection
from intramuscular (i.m.) injection of a lethal RABV by intrathecal
injection of an attenuated RABV (Baer et al., 1975). Importantly,
inactivated RABV could not protect dogs from death in these
experiments. Since that time, other animal model experiments
have demonstrated the ability of live-attenuated RABV to protect
against infection with lethal wild-type RABV (Franka et al., 2009;
Faber et al., 2009; Li et al., 2012; Schutsky et al., 2013). These data
indicate that treatment with attenuated RABV has the potential to
protect individuals who would otherwise succumb to rabies.
While questions of reverse mutations and safety persist, the
effectiveness of GAS RABV variants, with two attenuating muta-
tions in their glycoproteins, has been well established (Faber et al.,
2009; Li et al., 2012; Schutsky et al., 2013). Much of the success of
the GAS variants has been attributed to rapid induction of virus
neutralizing antibody (VNA) (Faber et al., 2009; Schutsky et al.,
2013). In order to be an effective late PET vector, the virus should
initiate an immune response much faster than the typical time
that is required to induce a robust VNA response. We recently
showed that the addition of IFNγ to a pathogenic RABV backbone
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highly attenuates the virus and enhances the innate immune
response, speciﬁcally through induction of type I interferons
(Barkhouse et al., 2014). Therefore, we constructed two new
IFNγ-expressing GAS vectors, GASγ and GASγGAS, to determine
if IFNγ expression by a highly attenuated vaccine vector could
increase its safety proﬁle and/or its efﬁcacy as pre- and post-
exposure treatment.
Results
Virus constructs
The wild-type RABV genome as well as the engineered viruses
SPBNγ, GASγ, GASGAS, GASγGAS, and GASoGAS are depicted in
Fig. 1A–F, respectively. SPBNγ is an attenuated RABV but still
retains residual pathogenicity in adult mice. GASγ is the next
generation IFNγ-producing RABV constructed using the highly
attenuated GAS backbone. The GAS virus has two engineered
mutations in its glycoprotein, the R333E mutation renders it
attenuated and the N194S mutation increases the safety of this
virus by drastically reducing the odds of a revertant mutation
(N194K) (Faber et al., 2005). The GAS glycoprotein is known to act
as a dominant negative, capable of preventing the pathogenicity
inherent in the wild-type glycoprotein when both are present
(Faber et al., 2007). Therefore, the GASγGAS backbone vector has
an improved safety proﬁle over GASγ as reversion to a pathogenic
phenotype would require unlikely mutations in both glycoprotein
genes. GASGAS is the control vaccine strain to which GASγ is
compared and GASoGAS is the control virus for GASγGAS mixed
infections.
GASγ and GASγGAS in vitro growth varies by cell type
An effective live-attenuated vaccine or PET vector must be able
to infect target cells and replicate. To ensure that GASγ and
GASγGAS can replicate and produce progeny virions, we created
growth curves using GASGAS as the control virus. We infected NA
and AS cells at an MOI¼1 for all three viruses (Fig. 2A, B). At 12, 24
and 48 h p.i. we collected supernatants from each of the virus-
infected cell cultures and calculated virus titers. At all timepoints
there is less than one log10 difference in virus titer between GASγ
or GASγGAS and control GASGAS in NA and AS cells, showing that
GASγ and GASγGAS can infect and replicate in CNS-relevant cells
as well as the GASGAS vaccine strain. The growth characteristics of
GASoGAS were previously determined and differ by less than one
log10 compared to GASγ, GASγGAS, or GASGAS (Badiane, 2011). We
also infected MC cells with the same three GAS variants to ensure
that the IFNγ expressed by GASγ and GASγGAS is functional
(Fig. 2C). The fact that GASGAS grows well (4105 ffu/ml) in MC
cells while GASγ and GASγGAS infected MC cells produced no
progeny virus in their supernatants, suggests that the activation of
MC cells by IFNγ is preventing virus propagation. Fig. 2D is an IFNγ
ELISA showing the presence of murine IFNγ in the 72-hour
Fig. 1. RABV constructs. A, The negative-stranded RNA genome of the wild-type
(WT) parental vector, SAD B19. B, The IFNγ-expressing RABV, SPBNγ. C, The IFNγ-
expressing GASγ, previously attenuated by two mutations in its glycoprotein gene.
D, The highly attenuated GASGAS control vaccine vector. E, The IFNγ-expressing
GASγGAS. F, The ovalbumin–expressing control vector GASoGAS. N, nucleoprotein;
P, phosophoprotein; M, matrix protein; G, glycoprotein; L, large catalytic subunit of
the viral polymerase; Ψ, pseudogene region; N194S and R333E, engineered
mutations; γ, murine IFNγ gene; ova, chicken ovalbumin gene.
Fig. 2. In vitro growth of GAS variants. NA, AS and MC cell lines were infected with GASGAS, GASγ, or GASγGAS at an MOI¼1 (A-C). Supernatant virus titers were measured
at the indicated times post-infection. D shows IFNγ present in the supernatants of BSR cells 72 hours p.i. Signiﬁcant difference was determined by the student's t-test.
*, pr0.05.
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supernatants of GASγ- and GASγGAS-infected BSR cells while no
IFNγ is detected in the GASGAS control supernatant. It should be
noted that more IFNγ is present in the GASγ supernatant com-
pared to GASγGAS.
IFNγ reduces pathogenicity of RABV in suckling mice
One of the hallmarks of a safe vaccine is its lack of pathogenicity
in immunocompromised mice. Having previously demonstrated that
virus-encoded IFNγ can strongly attenuate a pathogenic RABV
(Barkhouse et al., 2014), we hypothesized that a similar strategy
could increase the safety of a known vaccine strain. To test this
hypothesis we infected, intracranially (i.c.), groups of ﬁve-day-old
suckling mice with 103 ffu of SPBNγ, GASγ, GASγGAS, or GASGAS
control vaccine and monitored them for 40 days for mortality and
morbidity. The survival curves (Fig. 3) demonstrate that SPBNγ is
100% lethal at this dosage in the suckling mice. This result is not
surprising since we have shown that SPBNγ retains residual patho-
genicity in adult mice (Barkhouse et al., 2014). The pathogenicity of
SPBNγ, however, is similar to that of the GASGAS vaccine strain
which also kills 100% of mice. As hypothesized, the incorporation of
IFNγ into the GAS and GASGAS vectors results in signiﬁcant attenua-
tion of GASγ and GASγGAS as compared to the GASGAS vaccine with
30% of GASγ-infected and 45% of GASγGAS-infected suckling mice
surviving 40 d.p.i.
GASγ is an effective pre-exposure vaccine
To determine if IFNγ expression by a vaccine vector could affect
its ability to protect against lethal challenge, we infected groups of
ten mice i.m. in the gastrocnemius with 102–105 ffu of GASγ or
control GASGAS and challenged them 13 days post-vaccination
with 103 ffu of DRV4 i.c. Fig. 4A shows absolute survival percen-
tages and Fig. 4B is the survival curve providing both survival
percentages and time to death. There is no signiﬁcant difference in
protection when comparing GASγ to GASGAS vaccination using a
dose of 102 ffu, but at 103 ffu GASγ protects signiﬁcantly more
mice than GASGAS. As we increase to high vaccination doses (104
and 105 ffu), the efﬁcacy of GASGAS vaccine is equivalent to GASγ
for a 103 ffu DRV4 i.c. challenge, and 100% of mice in these dosage
groups survive for 28 days post-challenge. From these survival
data we show that the ED50 of GASγ is less than 1/3 that of
GASGAS (Fig. 4C).
GASγ protects mice from lethal co-infection
Having proven the increased efﬁcacy of GASγ over GASGAS as a
standard pre-exposure, live-attenuated vaccine, we next tested its
ability to protect mice from DRV4 during an i.c. mixed infection. Co-
infection serves a model of post-exposure treatment since we are
administering the treatment vector at the same time as the DRV4
reaches the brain. To determine the efﬁcacy of GASγ to protect mice
from lethal DRV4 i.c. infection as compared to GASGAS, we infected
Fig. 3. Infection of suckling mice. Five-day-old suckling mice were infected i.c. with
103 ffu of the indicated virus and monitored for mortality and morbidity for 40
days. Signiﬁcant difference between survival curves was determined by the
Mantel-Cox test. ***, pr0.001 and denotes the difference between the speciﬁc
curve and the GASGAS control curve.
Fig. 4. Survival after immunization and challenge. Groups of mice were immunized i.m. in the gastrocnemious with 102–105 ffu of GASGAS or GASγ followed by i.c. challenge
with 103 ffu of DRV4 13 days later. They were monitored for mortality and morbidity for 28 days post-challenge. A is a summary of the survival proportions while B shows
the survival curves. An ED50 comparison of GASGAS and GASγ is shown in C. Signiﬁcant difference between survival curves was determined by the Mantel-Cox test.
*, pr0.05 and denotes the difference between the GASγ curve and the GASGAS curve at the same immunization dosage. ■, 102 ffu; ◆, 103 ffu; ◆, 104 ffu; ●, 105 ffu; ◇, non-
immunized control.
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groups of mice with a mixture of 102 ffu of DRV4 and 103, 104, 105, or
106 ffu of GASγ or GASGAS. The survival proportions are represented
in Fig. 5A and the survival curves are shown in Fig. 5B. At 103 ffu of
GASγ or GASGAS there is no signiﬁcant difference in the ability of the
viruses to protect mice from death. As we increase the virus dosage,
GASγ is signiﬁcantly better at protecting against DRV4 infection.
104 ffu of GASγ protects 60% of mice from death while GASGAS
prevents death in only 10% of mice. For the sake of clarity, Fig. 5C
shows the 104 ffu survival curves from Fig. 5B. For the higher doses of
virus (105 and 106 ffu), the ability of GASγ to protect mice from death
during mixed infection is not statistically different than GASGAS.
Survival proportions were used to calculate the ED50 of GASγ and
GASGAS. The ED50 of GASγ is approximately seven fold lower than
that of GASGAS (Fig. 5D).
Post-exposure treatment with GASγGAS reduces neurological
sequelae
GASγGAS is a potentially more attractive candidate for a PET
compared to GASγ. GASγGAS has an improved safety proﬁle due, at
least in part, to the presence of the second GAS gene (Faber et al.,
2007). In order to control for the increased genome size and the
production of additional virus-encoded proteins (IFNγ and GAS) by the
host cellular machinery, we used GASoGAS as a control virus. As a
model of post-exposure treatment, we infected groups of mice i.c.
with a mixture of 103 ffu of DRV4 and 103, 104, 105, or 106 ffu of
GASγGAS or GASoGAS (Fig. 6A). Survival curves show no signiﬁcant
differences in protection from DRV4 infection between GASγGAS and
GASoGAS at any treatment dose (Fig. 6A). GASγGAS is effective at
preventing death due to DRV4 infection, however, as 50% and 100% of
mice treated with 105 or 106 ffu of GASγGAS survive, respectively.
Interestingly, we observed qualitative differences in the behaviors of
mice treated with GASγGAS versus those treated with GASoGAS. The
GASoGAS-treated mice were very aggressive (especially unusual for
female mice and a trait not observed prior to infection) and had
tremors, whereas the GASγGAS-treated mice showed no unusual
behavior. We used the hanging wire test to quantitate speciﬁc
behavioral differences between mice treated with 106 ffu of GASγGAS
or GASoGAS. The results show the GASoGAS-treated group has a
signiﬁcant deﬁcit in motor neuromuscular function compared to the
GASγGAS-treated mice as determined by the falls score of each
treatment group (Fig. 6B).
Fig. 5. Survival after mixed infection. Groups of mice were infected with a mixture of 102 ffu of DRV4 and 103–106 ffu of GASGAS or GASγ and monitored for mortality and
morbidity for 30 days. Survival proportions and survival curves for each virus are represented in A and B, respectively. C shows survival curves of the 104 ffu treatment dose
only. The ED50 of each treatment virus is found in D. Signiﬁcant difference between survival curves was determined by the Mantel-Cox test. **, pr0.01 and denotes the
difference between the GASγ curve and the GASGAS curve at the same immunization dosage. ■, 103 ffu; ◆, 104 ffu; ◆, 105 ffu; ●, 106 ffu; ◇, non-immunized control.
Fig. 6. Mortality and morbidity after mixed infection. Groups of mice were infected with a mixture of 103 ffu of DRV4 and 103–106 ffu of GASoGAS or GASγ and monitored for
mortality and morbidity for 28 days. Surviving mice from the 106 ffu treatment groups were then tested for motor neuromuscular function by the hanging wire test. Survival
curves are shown in A, and B represents the fall scores of the surviving mice. Signiﬁcant difference between fall scores was determined by the Mantel-Cox test. **, pr0.01. ■,
103 ffu; ◆, 104 ffu; ◆, 105 ffu; ●, 106 ffu; ◇, non-immunized control.
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Discussion
Previous work demonstrating the importance of IFNγ during
RABV clearance from the CNS (Hooper et al., 1998; Phares et al.,
2006, 2007; Hooper et al., 2011) and during in vitro infection of
antigen presenting cells (Li et al., 2008) led us to hypothesize
that overexpression of IFNγ by the RABV itself could attenuate
pathogenicity, enhance immunogenicity, and aid clearance of
pathogenic RABV from the CNS. Furthermore, the clearance
of other neurotropic viruses from the CNS is known to be
IFNγ-dependent (Grifﬁn, 2010; Patterson et al., 2002) We recently
demonstrated the attenuating effects of IFNγ expressed by an
otherwise pathogenic RABV (Barkhouse et al., 2014), but this virus
retains residual pathogenicity in adult mice that precludes its use
as a safe PET. Therefore, we constructed next-generation IFNγ-
expressing RABVs, GASγ and GASγGAS, using the highly attenu-
ated GAS and GASGAS backbones proven to be non-pathogenic in
adult mice (Faber et al., 2005, 2007, 2002).
We conﬁrmed previous work showing that the highly atte-
nuated GASGAS virus we used as a control for many experi-
ments is, indeed, lethal for ﬁve-day-old suckling mice (Faber et
al., 2009). Interestingly, the addition of IFNγ to the GAS back-
bone makes GASγ signiﬁcantly more attenuated in suckling
mice compared to the GASGAS control virus. This ﬁnding is
notable because attenuated RABVs containing two glycoprotein
(G) genes are less pathogenic and more immunogenic than their
single G counterparts owing to G protein overexpression (Faber
et al., 2002; Liu et al., 2014). Therefore, RABV-expressed IFNγ
can attenuate the virus to a higher degree than overexpression
of G protein alone. We further show that these two attenuating
modiﬁcations are additive in that insertion of the IFNγ gene to
the GASGAS backbone virus creates a vaccine strain, GASγGAS,
which is even more attenuated than GASγ. Although it is
evident that IFNγ expression by GASγ strongly attenuates the
virus, it is unclear whether the amount of IFNγ produced by the
virus is ideal. It is conceivable that the greater attenuation of
GASγGAS over GASγ in suckling mice may, at least in part, be a
consequence of its more controlled production of IFNγ, as seen
in culture. IFNγ expression can contribute to the pathogenesis of
certain CNS viral infections but is more commonly found to be
neuroprotective reviewed in Rottenberg and Kristensson, 2002.
Thus we consider that the synergy between increased IFNγ
production and overexpression of attenuated G protein account
for the decrease in pathogenicity of GASγGAS in suckling mice
compared to GASγ.
The effect of IFNγ delivered in cis or in trans with various
experimental pre-exposure vaccine vectors has been demon-
strated previously. Expression of IFNγ by plasmid transfection at
the site of vaccination against very virulent Marek's Disease Virus
(vvMDV) signiﬁcantly protects chickens from tumor development
as compared to control vaccination (Haq et al., 2011). Additionally,
a Simian Immunodeﬁciency Virus (SIV) expressing IFNγ sup-
presses viremia after lethal challenge, although it cannot prevent
persistent infection with the virulent challenge strain (Giavedoni
et al., 1997). Similarly, we have shown that pre-exposure vaccina-
tion with GASγ, despite its lack of G protein overexpression,
protects signiﬁcantly more mice against lethal challenge than the
control GASGAS vaccination. More importantly, however, GASγ
protects mice from death due to challenge as opposed to simply
limiting aspects of morbidity. The signiﬁcantly greater protection
offered by GASγ occurs at low dosage and the effect diminishes as
pre-exposure dosage increases. A larger challenge virus dosage
may be required to determine if higher doses of GASγ are similarly
more efﬁcacious than GASGAS at the lower dose, as there appears
to be a threshold level of protection that is attained by both GASγ
and GASGAS as we increase the vaccine dose.
Although enhancing the safety and efﬁcacy of live-attenuated pre-
exposure vaccines will assist in the efforts to eradicate terrestrial
rabies and has the potential to make rabies vaccination more
affordable and accessible, the primary goal of this research is to
determine the feasibility of using a live-attenuated virus as late post-
exposure treatment. Currently, there is no universally effective
treatment for clinical rabies and even the success of the Milwaukee
Protocol (Willoughby et al., 2005) is contested (Jackson, 2011). We
used mixed i.c. infection as a model of late PET since the treatment
and challenge viruses reach the brain simultaneously. As with pre-
exposure treatment, GASγ protects signiﬁcantly more mice than
GASGAS during i.c. mixed infection with lethal DRV4 at the relatively
low treatment dose of 104 ffu. When higher doses of 105 and 106 ffu
are used, both treatment viruses protect equally well. As proposed
above, a larger dose of challenge virus may be necessary to
discriminate between GASγ and GASGAS efﬁcacies at higher treat-
ment doses. Thus we have demonstrated the superior efﬁcacy of an
IFNγ-expressing RABV as pre- and post-exposure treatment over a
highly attenuated control vaccine.
The lowest tested dose of both GASγ and GASGAS (103 ffu)
protects relatively few mice from DRV4 mixed i.c. infection.
Although 103 ffu of pre-exposure virus has time to replicate,
spread, and induce sterilizing immunity, this dose is unlikely to
have sufﬁcient initial antigenic load to rapidly induce the level
of immunity required for PET. Doses as much as 107–109 ffu of
live-attenuated virus have previously been used for successful
PET (Faber et al., 2009; Wu et al., 2011) while 105 ffu was
effective here. These types of experiments often compare the
efﬁcacy of live-attenuated RABV to inactivated RABV vaccine as
well (Liu et al., 2014; Wu et al., 2011). We show that relatively
low doses of IFNγ-expressing RABV, GASγ, used for pre- and
post-exposure treatment are highly efﬁcacious and better pro-
tect mice than the already established vaccine vector, GASGAS.
IFNγ-expressing RABV vectors have many potential advantages
over traditional live-attenuated RABV vaccines. First, the lower
effective dose equates to less cost per treatment, whether being
used as a pre-exposure vaccine or PET. Lowering the cost of
RABV vaccines will make vaccinating and treating humans and
dogs a more attainable goal in regions of the world with very
limited ﬁnancial resources. PET with a lower effective dose of
vaccine also has the potential to limit the chance of the
treatment vector contributing to CNS pathology. Finally, the
rapid production of IFNγ by a RABV vector induces an innate
response earlier than similar vectors not expressing IFNγ,
potentially lengthening the window of successful PET.
GASγGAS is potentially a better PET candidate due to over-
expression of G protein as well as the dominant negative effect of a
second copy of the G gene with respect to reversion. To control for
the increased genome size and the potential host cell machinery
stress due to additional expression of virus-encoded genes (GAS
and IFNγ), we used GASoGAS as the control for i.c. mixed infection
with GASγGAS. We found no signiﬁcant difference in the ability of
GASγGAS to protect mice from lethal DRV4 infection at any
treatment dose. The additional attenuation of the GASGAS back-
bone compared to GAS may result in GASγGAS being able to
replicate and spread less efﬁciently in the brain, thereby attenuat-
ing the virus too much to be effective PET. For the same reason, the
GASγGAS virus may express less IFNγ in the CNS, as seen in BSR
cells. Alternatively, a larger challenge dose may be needed to
discern any differences in efﬁcacy between GASγGAS and GASo-
GAS. We did observe neurological differences between GASγGAS
and GASoGAS at the 106 ffu dose. Neurological sequelae were
reduced in the GASγGAS treated group as determined by the
hanging wire test. Therefore, GASγGAS shows improved efﬁcacy
over its control in terms of reduction in motor neuromuscular
deﬁcit incurred during PET.
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These data demonstrate that expression of murine IFNγ by an
already highly attenuated RABV vector can enhance its safety
proﬁle in immunocompromised mice, improve its efﬁcacy as a
pre-exposure vaccine, better protect mice from lethal co-infection
and reduce neurological sequelae after PET. Therefore, delivery of
IFNγ by a live-attenuated vector has the potential to improve pre-
exposure vaccine efﬁcacy, but more importantly, may be able to
act as late PET for those individuals who would otherwise die from
rabies.
Materials and methods
Viruses
GAS and GASGAS viruses have been described elsewhere (Faber
et al., 2005, 2007) and are fully recombinant vectors based on the
prototype recombinant RABV derived from the SADB19 strain
(Conzelmann et al., 1990; Schnell et al., 1994). The wild type RABV
strain DRV4 was isolated from a human rabies victim and
propagated in NA cells as previously described (Dietzschold et
al., 2000).
Recombinant virus construction
The recombinant RABVs, SPBNγ, GASγ, GASγGAS, and GASoGAS
were engineered as described previously (Faber et al., 2005). As a
brief example, for SPBNγ murine IFNγ DNA was PCR-ampliﬁed
from mRNA extracted from RABV-infected mouse brain tissue
using the custom primers (IDT, Coralville, IA) below and DeepVent
polymerase (NEB, Ipswich, MA). The forward primer, 5’ATA-
GAATTCCGTACGAAGATGAACGCTACACACTGCATCTTGGCT3’, contains
a BsiWI restriction site, start codon, and the gene speciﬁc sequence.
The reverse primer, 5’ATTCTCTAGATAGCTAGCTCAGCAGCGACTCC-
TTTTCCGCTTCCT3’, contains a NheI restriction site, stop codon, and
the gene speciﬁc sequence. The resultant IFNγ DNA was cloned into
the pSPBN plasmid, creating the pSPBNγ plasmid. Standard trans-
formation and transfection methods were used to complete the
virus rescue of SPBNγ as outlined above.
Cell lines
BSR cells (a BHK-21 clone) (Macpherson and Stoker, 1962)
grown in DMEM (Mediatech, Manassas, VA) supplemented with
10% FBS (Atlanta Biologicals, Flowery Ranch, GA) were used to
grow virus stocks. Mouse neuroblastoma cells (NA) were grown in
RPMI medium 1640 (Mediatech, Manassas, VA) and used for
growth curves and virus titers. Mouse astrocytoma (AS) cells and
monocyte lineage (MC) cells were grown in DMEM supplemented
with 10% FBS and were used for growth curves.
Growth curves
NA, AS, or MC cells were infected at a multiplicity of infection
(MOI) of 1 for growth curves. 100 ul supernatant aliquots were
taken at 0, 12, 24, and 48 hours post-infection. Virus titers from the
supernatants were calculated as described below.
Virus titers
To determine virus titers, NA cells were seeded into 96 well
plates, grown for two days and then infected with virus in serial
ten-fold dilutions. Two days post-infection (d.p.i.), the cells were
ﬁxed with 80% acetone and stained with FITC-conjugated anti-
RABV RNP antibody (Fujirebio Diagnostics, Malvern, PA). Virus
titers of quadruplicate samples were determined using a ﬂuores-
cence microscope.
Mice
Female, six to eight week old and timed pregnant Swiss
Webster mice were purchased from Taconic Farms (Germantown,
NY). All mouse experiments were approved by the Thomas
Jefferson University Institutional Animal Care and Use Committee.
Infection of mice
Groups of ten adult mice were infected under isoﬂurane
(Vedco, St. Joseph, MO) anesthesia: 1) intracranially (i.c.) with 102
or 103 focus-forming units (ffu) of challenge virus in 10 ul PBS, 2) i.c.
with a mixture of 102 or 103 ffu of challenge virus with 103–106 ffu
of attenuated virus in 10 ul PBS or 3) intramuscularly (i.m.) in each
gastrocnemious with 102–105 ffu of attenuated vector in 100 ul PBS.
Mice were observed for 28–30 days for appearance of clinical signs
of rabies such as limb paralysis, tremors, and weight loss. Litters of
10–12 ﬁve-day-old suckling mice were infected i.c. with 103 ffu
of RABV in 5 ul PBS and observed 40 days for mortality and
morbidity. All mice were humanely euthanized when moribund
or after losing greater than 30% of starting body weight.
IFNγ enzyme-linked immunosorbent assay (ELISA)
50 ul aliquots of virus-infected supernatants were assayed for
IFNγ using an OptEIA Mouse IFNγ Kit II (BD Biosciences, San Jose,
CA) per manufacturer’s instructions. The plates were then scanned
in a Synergy H1 plate reader (BioTek, Winooski, VT) and absor-
bance at 450 nm was recorded.
Behavioral testing
The hanging wire test was used to assess motor neuromuscular
impairment in mice that survived RABV infection. The procedure,
derived from the taut wire test and SHIRPA phenotypic assessment
of mdx mice (Gomez et al., 1997; Rafael et al., 2000) can be found
here (http://www.treat-nmd.eu/downloads/ﬁle/sops/dmd/MDX/
DMD_M.2.1.004.pdf). Brieﬂy, mice are suspended from a taut wire
and latency to fall is measured as an indicator of gross motor
neuromuscular condition.
Statistical analysis
All calculations were performed using GraphPad Prism 5.01
(GraphPad Software, San Diego, CA) with the exception of the
Habel Test for Potency (World Health Organization, 1996).
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